OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA LDA
Ophiomics is a start up company that develops innovative Precision Medicine tools for Liver Cancer. We integrate artificial intelligence to support better clinical decision making. We will be showcasing our first market ready prodcut at Arab Health 2022 - HEPATOPREDICT - a gene expression signature measured in a liver cancer biopsy, coupled to an AI-based algorithm that can identify with high sensitivity and specificity patinets that will benefit from curative intent liver surgery, in particular liver transplantation. HepatoPredict is a qPCR-based kit with a CE IVD marking and pending ISO13485 and 9001 certifications, that can be used in a pathology laboratory supporting Hpatology and Hepatobiliary Surgery Centres. We wil also showcase HEPATODETECT, our under-validation liquid biopsy for early detection of liver cancer in cirrhotic patients.